StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.61+0.01 (+0.63%)

Close on Nov 18, 2026Market cap $80.25MP/E –Yield –

Polaryx Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Polaryx Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$7.58M. For fiscal 2025 it was -$7.82M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.82M–
FY2024Dec 31, 2024-$4.35M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.33M–
Q2 FY2026Jun 30, 2026-$1.38M–
Q1 FY2026Mar 31, 2026-$1.96M–
Q4 FY2025Dec 31, 2025-$911.00K–
Q3 FY2025Sep 30, 2025-$974.00K–
Q2 FY2025Jun 30, 2025-$884.00K–
Q1 FY2025Mar 31, 2025-$5.05M–

More Polaryx Therapeutics figures

See a number that looks wrong?